Catalyst Pharmaceuticals Net Income

The latest net income for CPRX is $220M as of March 2026. That compares with $200M in the prior-year period — up 12.1% year over year. That is below the Healthcare sector average of $17B. Investors often review this figure alongside Catalyst Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, CPRX's net income moved from $200M to $220M — a 12.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Catalyst Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, CPRX currently prints $220M for net income, while the sector average sits near $17B. That is roughly 98.7% below the sector mean. Large gaps often invite a closer look at Catalyst Pharmaceuticals's growth, margins, and balance sheet.

A net income figure of $220M for CPRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $17B. Explore the charts below for those layers of context.

After noting CPRX's net income ($220M), review year-over-year change from $200M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.